Johnson & Johnson (JNJ)vsNuvalent Inc (NUVL)
JNJ
Johnson & Johnson
$276.25
+1.43%
HEALTHCARE · Cap: $657.68B
NUVL
Nuvalent Inc
$123.96
0.00%
HEALTHCARE · Cap: $9.81B
Smart Verdict
WallStSmart Research — data-driven comparison
JNJ leads profitability with a 16.2% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
NUVL
Avoid25
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Safe zone — low bankruptcy risk
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 8.3x book value
0.0% revenue growth
0.0% earnings growth
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : NUVL
The strongest argument for NUVL centers on Altman Z-Score.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : NUVL
The primary concerns for NUVL are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
JNJ profiles as a mature stock while NUVL is a value play — different risk/reward profiles.
NUVL carries more volatility with a beta of 1.14 — expect wider price swings.
JNJ is growing revenue faster at 5.9% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 25/100), backed by strong 16.2% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Nuvalent Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Nuvalent Inc. is a clinical-stage biopharmaceutical company specializing in precision oncology, dedicated to the development of targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to innovate therapeutics that specifically address genetic mutations linked to tumor proliferation, thus enhancing treatment efficacy while minimizing adverse effects. With a promising pipeline of selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating its commitment to revolutionizing cancer treatment and improving patient outcomes.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?